8-K: AbCellera's ABCL635 Enters Phase 2 for Menopause VMS

AbCellera Biologics Inc. announced the dosing of first patients in the Phase 2 portion of its ABCL635 clinical trial for moderate-to-severe vasomotor symptoms due to menopause, with top-line results expected in Q3 2026.

Summary

• AbCellera Biologics Inc. has initiated the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
• The advancement to Phase 2 follows an interim review of encouraging safety, tolerability, and pharmacodynamic data from the Phase 1 healthy volunteer portion.
• The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate ABCL635's efficacy in 80 postmenopausal women.
• Top-line clinical results for both Phase 1 and Phase 2 are anticipated in Q3 2026.
• ABCL635 targets NK3R, a clinically validated G protein-coupled receptor, and is the first program from AbCellera's GPCR and ion channel platform to enter clinical development.
• The company maintains approximately $680 million in liquidity as of September 30, 2025, to execute its strategy.
• AbCellera also has ABCL575 (OX40L antagonist for Atopic Dermatitis) in Phase 1, with readout anticipated mid-2026, and two programs (ABCL688, ABCL386) in IND-enabling activities.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with a key pipeline asset (ABCL635) advancing to Phase 2 after positive Phase 1 data, targeting a significant market with a differentiated profile. The company also highlights a robust broader pipeline and strong liquidity, suggesting good operational health and future growth potential. No explicit negatives or delays were reported.

Positives

• ABCL635, a potential first-in-class non-hormonal treatment for VMS, has successfully advanced to Phase 2 following encouraging safety and pharmacodynamic data from Phase 1.
• The Phase 2 study is well-designed as a multicenter, randomized, double-blind, placebo-controlled trial, aiming to evaluate efficacy in 80 postmenopausal women.
• ABCL635 targets NK3R, a clinically validated pathway, and is the first program from AbCellera's GPCR and ion channel platform to reach the clinic, validating the platform.
• The company anticipates top-line clinical results for ABCL635's Phase 1/2 trial in Q3 2026, providing a clear near-term catalyst.
• ABCL635 is designed to offer potential advantages over current non-hormonal treatments, including reduced toxicities (no expected liver toxicity or CNS depressant effects), dosing flexibility (monthly subcutaneous injection preferred by over 50% of women), and enhanced efficacy.
• The market for novel non-hormonal VMS treatments is estimated to exceed $2 billion, with approximately 6 million women in the US suffering from moderate-to-severe VMS.
• AbCellera has a strong liquidity position of approximately $680 million as of September 30, 2025, supporting its pipeline development.
• The company has a robust internal pipeline with ABCL575 in Phase 1 for Atopic Dermatitis (readout mid-2026) and two additional development candidates (ABCL688, ABCL386) in IND-enabling studies.
• AbCellera's partner portfolio includes 16 molecules that have reached the clinic, demonstrating the strength of its discovery platform and providing potential future royalty revenue with a mean royalty rate of 3.2%.

Risks

• Actual results, levels of activity, performance, or achievements may be materially different from forward-looking statements due to various risks, uncertainties, and other factors.
• Inability to develop, commercialize, and achieve market acceptance of current and planned products and services.
• Uncertainties related to research and development efforts.
• Risks associated with business strategies, use of capital, results of operations, financial position, and plans and objectives for future operations.
• Forward-looking statements are based on a combination of facts and factors currently known and projections of the future, about which the company cannot be certain, and may not prove to be accurate.

Future Outlook

AbCellera anticipates top-line clinical results for its ABCL635 Phase 1/2 trial in Q3 2026 and for its ABCL575 Phase 1 trial in mid-2026. The company plans to advance ABCL688 and ABCL386 through IND-enabling studies in 2026 and nominate at least one additional development candidate. Potential catalysts for 2027 include late-stage development of ABCL635 in menopausal VMS, initiation of ABCL635 Phase 2 studies in oncology VMS, and IND submissions for ABCL688, ABCL386, and a new development candidate, with an expectation of producing 1-2 development candidates per year from its discovery programs.

Management Comments

• "Advancing this program into Phase 2 marks an important milestone in our clinical development efforts."
• "Based on encouraging safety and pharmacodynamic data in the Phase 1 dose escalation portion, along with evidence of high target engagement and a strong mechanistic foundation, we are eager to evaluate ABCL635 in a randomized, double-blind Phase 2 study."
• "Menopausal symptoms can have a profound impact on quality of life, and we look forward to evaluating the potential of ABCL635 to provide a safe and effective option for women seeking non-hormonal symptom relief."

Industry Context

The advancement of ABCL635 into Phase 2 positions AbCellera in the growing market for non-hormonal treatments for vasomotor symptoms (VMS) due to menopause, estimated to be over $2 billion. This market is driven by a significant unmet need among women who are contraindicated for or choose not to use Menopause Hormone Therapy (MHT). The company is entering a competitive landscape with recently approved small molecule NK3R antagonists like Fezolinetant (Astellas) and Elinzanetant (Bayer), but aims to differentiate ABCL635 through its antibody-based approach, potentially offering improved safety profiles (e.g., reduced liver toxicity, no CNS effects) and a more convenient monthly subcutaneous dosing schedule. Similarly, ABCL575 for Atopic Dermatitis targets an $11 billion+ market with a need for alternatives beyond existing IL-13 and IL-4/13 classes, indicating AbCellera's strategy to target high-value indications with differentiated antibody therapies.

Comparison to Industry Standards

• ABCL635 is an antibody-based NK3R antagonist, differentiating it from recently approved small molecule NK3R antagonists like Fezolinetant (Veozah) by Astellas and Elinzanetant (LynkuetTM) by Bayer.
• Fezolinetant, approved May 12, 2023, is a daily oral treatment with a boxed warning for liver toxicity, requiring liver monitoring.
• Elinzanetant, approved October 24, 2025, is also a daily oral treatment with warnings for CNS depressant effects, daytime impairment, and liver enzyme elevation, also requiring liver monitoring.
• ABCL635, as an antibody, is generally not associated with drug-related liver toxicity and, by not antagonizing NK1R, is not expected to induce fatigue or somnolence, potentially offering a superior safety profile compared to these small molecule competitors.
• ABCL635's proposed monthly (Q4W) subcutaneous dosing schedule is preferred by over 50% of women with VMS compared to daily oral treatments, offering a significant convenience advantage.
• ABCL575 for Atopic Dermatitis aims to provide an alternative to existing treatments like dupilumab, where over 20% of patients discontinue, indicating a need for new mechanisms of action or improved profiles.

Stakeholder Impact

• Shareholders: Positive impact due to clinical pipeline progression, potential for future revenue from ABCL635, and strong liquidity.
• Patients (Women with VMS): Potential for a new, differentiated, non-hormonal treatment option with a better safety and dosing profile compared to existing therapies.
• Employees: Continued progress in clinical development and pipeline expansion suggests stability and growth opportunities.
• Partners: Continued validation of AbCellera's platform capabilities could attract new partnerships and strengthen existing relationships.

Next Steps

• Continue Phase 2 clinical trial for ABCL635 in postmenopausal women with VMS.
• Anticipate top-line clinical results for ABCL635 Phase 1/2 trial in Q3 2026.
• Continue Phase 1 clinical trial for ABCL575 for Atopic Dermatitis.
• Anticipate readout of ABCL575 Phase 1 clinical study in mid-2026 (H2 2026).
• Progress ABCL688 and ABCL386 through IND-enabling studies.
• Nominate at least one additional development candidate for IND-enabling studies in 2026.
• Pursue late-stage development of ABCL635 in menopausal VMS in 2027.
• Initiate Phase 2 studies of ABCL635 in oncology VMS in 2027.
• Evaluate options for further development or out-licensing of ABCL575 in 2027.
• Submit INDs and initiate Phase 1/2 studies for ABCL688, ABCL386, and a new development candidate in 2027.
• Continue to produce 1-2 development candidates per year from 20+ discovery programs.

Key Dates

Recommendation

The advancement of ABCL635 to Phase 2 for a large, underserved market, coupled with encouraging Phase 1 data and a differentiated product profile, represents a significant de-risking event for AbCellera's internal pipeline. The company's strong liquidity, robust broader pipeline, and clear near-term catalysts (Q3 2026 readout for ABCL635) suggest a positive trajectory. While drug development carries inherent risks, the progress indicates strong execution and potential for substantial future value creation, making it an attractive investment for long-term growth.

Keywords

AbCellera Biologics, ABCL, ABCL635, Vasomotor Symptoms, Menopause, Clinical Trial, Phase 2, Biotechnology, Antibody Medicine, NK3R Antagonist, Drug Development, Womens Health, GPCR, ABCL575, Atopic Dermatitis, OX40L Antagonist, Pipeline, Biopharma